European Medicines Agency Adopts Positive Opinion for KEYTRUDA® (pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

European Medicines Agency Adopts Positive Opinion for KEYTRUDA® (pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

July 30, 2018 KEYTRUDA Combination Improved Overall Survival Compared with Pemetrexed and Platinum Chemotherapy Alone in Pivotal Phase 3 Trial (KEYNOTE-189) Positive Opinion for KEYTRUDA Also Adopted for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-040)

Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types

Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types

June 3, 2018 — First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the

LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer

Women with Platinum-Sensitive Ovarian Cancer Now Have Access to Maintenance Therapy with AstraZeneca and Merck’s LYNPARZA, Regardless of BRCA status LYNPARZA Has Over Five Years’ Efficacy and Safety Follow-Up Data New Tablet Formulation Reduces Dosing to Two Tablets Twice Daily Tuesday, May

Moderna and Merck Expand mRNA Cancer Vaccines Collaboration

Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna Thursday, May 3, 2018 4:15 pm EDT CAMBRIDGE, Mass. and KENILWORTH N.J. May 3, 2018 — Moderna Therapeutics and

Merck Provides Update on KEYNOTE-407 Trial

Thursday, May 3, 2018 6:45 am EDT KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel

Moderna and Merck Expand mRNA Cancer Vaccines Collaboration

Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna  Thursday, May 3, 2018 4:15 pm EDT  CAMBRIDGE, Mass. and KENILWORTH N.J. May 3, 2018 — Moderna Therapeutics and

FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as First-Line Treatment of Metastatic Nonsquamous NSCLC

U.S. FDA Has Set a PDUFA Date of Sept. 23, 2018 Monday, April 30, 2018 6:45 am EDT KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration

European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial

Monday, April 23, 2018 4:30 pm EDT KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the